Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2026-04-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（王兆钢）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate for Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report attachments. The document is a formal declaration related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and does not indicate it is an announcement of a report publication or a regulatory filing. Hence, the classification is MANG with high confidence.
2026-04-21 Chinese
2025年度独立董事述职报告（任勇）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by 任勇, an independent director of 江苏森萱医药股份有限公司. It details the director's qualifications, attendance at board and committee meetings, exercise of duties, communication with auditors, focus on protecting minority shareholders, and overall evaluation and suggestions for the company. The content is a detailed narrative of the independent director's activities and responsibilities over the year, rather than a financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a proxy solicitation or remuneration report. It is a governance-related report focusing on the independent director's role and duties, which fits best under Board/Management Information (MANG). The document length (6634 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2026-04-21 Chinese
2025年度独立董事述职报告（沈小燕）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告（沈小燕）" which translates to "2025 Annual Independent Director's Work Report (Shen Xiaoyan)". It is a detailed report by an independent director about her duties, attendance, and activities during the year 2025. The content includes descriptions of meetings attended, audit committee activities, communication with shareholders, and evaluations of company governance and financial reporting. It does not contain financial statements or quarterly/annual financial results but rather focuses on governance and director duties. This type of document is a management or board-related report focusing on director activities and governance oversight. It is not an annual report, audit report, earnings release, or other financial report. It is also not a simple announcement or certification. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements of changes or reports related to board or senior management activities, including independent director reports.
2026-04-21 Chinese
董事会关于2025年度独立董事独立性情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors for the year 2025. It references regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange concerning independent directors. The content focuses on the evaluation of the independence of specific directors and confirms their compliance with relevant independence criteria. There are no financial statements, earnings data, or other financial report content. The document is a governance-related disclosure about board members' independence, which fits best under Board/Management Information (MANG) as it relates to board composition and director status rather than a full governance report or proxy statement. The document length is short and it is not an announcement of a report but the report itself on director independence. Therefore, the classification is MANG with high confidence.
2026-04-21 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' (Internal Control Audit Report) issued by a certified public accounting firm (BDO China Shu Lun Pan Certified Public Accountants LLP) for 江苏森萱医药股份有限公司. It specifically addresses the audit of the effectiveness of internal control over financial reporting as of December 31, 2025. The document includes detailed descriptions of the company's internal control responsibilities, the auditor's responsibilities, the scope of the internal control evaluation, and the audit opinion on the effectiveness of internal controls. It also contains detailed internal control self-evaluation by the company, including governance, risk management, and control procedures. The document is about 9,901 characters long, which is substantial and contains the full audit report, not just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. It is not an Annual Report (10-K) because it focuses solely on internal control audit and evaluation, not the full financial performance. It is not a Regulatory Filing (RNS) because it contains substantive audit content, not just a certification or announcement. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-21 Chinese
2025年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2025. It contains detailed financial data including total assets, net assets, revenue, net profit, and shareholder information for multiple years, which is typical of an annual report. It also includes audit information mentioning a standard unqualified audit opinion by a CPA firm, which is common in annual reports. The document is over 5,000 characters and contains substantive financial data and analysis, not just an announcement or a certification. Therefore, this document is the actual Annual Report rather than an announcement or summary notice. FY 2025
2026-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.